Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis' : Iptacopan Shows Positive Results in Rare Blood Disorder Patients

06/11/2021 | 03:45am EDT


ę MT Newswires 2021
All news about NOVARTIS AG
11:34aIONIS PHARMACEUTICALS : Says Phase 3 Trial of Pelacarsen for Reducing Recurrent ..
MT
07/29Rubius Therapeutics Taps Dannielle Appelhans as Chief Operating Officer
DJ
07/28XOMA : Secures FDA's Orphan Drug Designation for Investigational Pancreatic Canc..
MT
07/28GLOBAL MARKETS LIVE : Apple, Alphabet, Facebook, Pfizer, McDonald's...
07/28XOMA Gets Orphan Drug Designation for Pancreatic Cancer Treatment
DJ
07/28NOVARTIS AG : Sell rating from JP Morgan
MD
07/27NOVARTIS : Gets US FDA's Orphan Drug Designation For Pancreatic Cancer Treatment
MT
07/27NOVARTIS : Morgan Stanley Lowers Price Target on Novartis, Maintains Overweight/..
MT
07/27NOVARTIS AG : Gets a Buy rating from Morgan Stanley
MD
07/27Artios raises USD153m in Series C financing
DJ
More news
Financials (USD)
Sales 2021 51 982 M - -
Net income 2021 9 881 M - -
Net Debt 2021 22 970 M - -
P/E ratio 2021 20,3x
Yield 2021 3,56%
Capitalization 225 B 226 B -
EV / Sales 2021 4,77x
EV / Sales 2022 4,46x
Nbr of Employees 109 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 92,51 $
Average target price 105,60 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG0.28%225 343
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
ELI LILLY AND COMPANY44.22%221 348
NOVO NORDISK A/S35.94%212 048